JP2024524527A5 - - Google Patents
Info
- Publication number
- JP2024524527A5 JP2024524527A5 JP2024500088A JP2024500088A JP2024524527A5 JP 2024524527 A5 JP2024524527 A5 JP 2024524527A5 JP 2024500088 A JP2024500088 A JP 2024500088A JP 2024500088 A JP2024500088 A JP 2024500088A JP 2024524527 A5 JP2024524527 A5 JP 2024524527A5
- Authority
- JP
- Japan
Links
Applications Claiming Priority (5)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP21183796 | 2021-07-05 | ||
| EP21183796.8 | 2021-07-05 | ||
| EP21184105.1A EP4116330A1 (en) | 2021-07-05 | 2021-07-06 | Multispecific antibodies with monovalent binding to tumor-associated antigens causing no or reduced nerve pain in the treatment of cancer |
| EP21184105.1 | 2021-07-06 | ||
| PCT/EP2022/068634 WO2023280880A1 (en) | 2021-07-05 | 2022-07-05 | Multispecific antibodies binding to tumor-associated antigens causing no or reduced nerve pain in the treatment of cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2024524527A JP2024524527A (ja) | 2024-07-05 |
| JPWO2023280880A5 JPWO2023280880A5 (https=) | 2025-05-12 |
| JP2024524527A5 true JP2024524527A5 (https=) | 2025-05-12 |
Family
ID=82656531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024500088A Pending JP2024524527A (ja) | 2021-07-05 | 2022-07-05 | がん治療において神経疼痛の消失または軽減をもたらす腫瘍関連抗原に結合する多重特異性抗体 |
Country Status (4)
| Country | Link |
|---|---|
| US (1) | US20240239916A1 (https=) |
| EP (1) | EP4330289A1 (https=) |
| JP (1) | JP2024524527A (https=) |
| WO (1) | WO2023280880A1 (https=) |
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2024040194A1 (en) | 2022-08-17 | 2024-02-22 | Capstan Therapeutics, Inc. | Conditioning for in vivo immune cell engineering |
| US12311033B2 (en) | 2023-05-31 | 2025-05-27 | Capstan Therapeutics, Inc. | Lipid nanoparticle formulations and compositions |
| WO2025076113A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Ionizable cationic lipids with conserved spacing and lipid nanoparticles |
| WO2025076127A1 (en) | 2023-10-05 | 2025-04-10 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| WO2025217454A2 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Ionizable cationic lipids and lipid nanoparticles |
| WO2025217452A1 (en) | 2024-04-11 | 2025-10-16 | Capstan Therapeutics, Inc. | Constrained ionizable cationic lipids and lipid nanoparticles |
| EP4684803A1 (en) | 2024-07-25 | 2026-01-28 | CeMM - Forschungszentrum für Molekulare Medizin GmbH | Antibody conjugated chemical inducers of degradation of rbm39 and therapeutic uses thereof |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4419399C1 (de) | 1994-06-03 | 1995-03-09 | Gsf Forschungszentrum Umwelt | Verfahren zur Herstellung von heterologen bispezifischen Antikörpern |
| CA2414148A1 (en) * | 2002-12-30 | 2004-06-30 | William Herman | Targeted ligands |
| WO2013189516A1 (en) * | 2012-06-18 | 2013-12-27 | Apeiron Biologics Ag | Method for treating a gd2 positive cancer |
| US11820832B2 (en) * | 2014-07-25 | 2023-11-21 | Memorial Sloan Kettering Cancer Center | Bispecific HER2 and CD3 binding molecules |
| TWI823906B (zh) * | 2018-03-09 | 2023-12-01 | 美商艾吉納斯公司 | 抗-cd73 抗體及其使用方法 |
-
2022
- 2022-07-05 US US18/577,197 patent/US20240239916A1/en active Pending
- 2022-07-05 JP JP2024500088A patent/JP2024524527A/ja active Pending
- 2022-07-05 EP EP22744699.4A patent/EP4330289A1/en active Pending
- 2022-07-05 WO PCT/EP2022/068634 patent/WO2023280880A1/en not_active Ceased